To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Mantle Cell Lymphoma

Brielle Urciuoli
This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.
Kevin Berry
One of the things I think about is the future. All cancer patients know we have two futures: One where things go well, and one where they don't.
Brielle Urciuoli
Deferring treatment may actually be beneficial for some patients with mantle cell lymphoma (MCL), according to recent research.
Brielle Urciuoli
While the treatment landscape of mantle cell lymphoma (MCL) has continued to evolve in recent years, researchers and clinicians alike are still at a loss for curative strategies. But immunotherapy may help.
Andre Goy, M.D., M.S.
Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.
Kristie L. Kahl
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
Michael Wang, M.D.
There are many exciting advances happening in the field of mantle cell lymphoma.
Jessica Skarzynski
Since its classification in 1994, the prognosis for patients diagnosed with mantle cell lymphoma (MCL) was generally poor; however, survival rates have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.
Kevin Berry
Moving from shock to action is hard, but it's critical to surviving cancer
Brielle Urciuoli
Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other